Myopia Market

Market Overview:

The 7 major myopia markets are expected to exhibit a CAGR of 6.14% during 2024-2034.

The myopia market has been comprehensively analyzed in IMARC's new report titled "Myopia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myopia, also known as nearsightedness, refers to a refractive error of the eye that makes distant objects appear blurry while close objects remain clear. It develops when the eyeball is too long or the cornea or lens is too curved, which causes light rays to be focused in front of the retina instead of directly on it. The main symptom of myopia is blurry vision when looking at things in the distance, such as road signs or chalkboards. Various other symptoms may include eye strain, headaches, and difficulty seeing at night or in dimly lit environment. In some cases, myopia may also cause squinting or the need to frequently adjust the distance between the eyes and the object being viewed. The diagnosis typically involves a comprehensive eye examination conducted by an optometrist or ophthalmologist. During the exam, the eye doctor uses a variety of tools and tests to measure the curvature of the cornea and the length of the eye, as well as assess the clarity of vision at different distances. The healthcare professional may also perform a retinal exam to check for any anomalies or signs of eye disease.

The growing prevalence of numerous associated risk factors, such as prolonged close-up activities, excessive screen time, lack of outdoor exposure, genetic predisposition, etc., is primarily driving the myopia market. Furthermore, the widespread adoption of atropine eye drops to dilate the pupils and reduce the progression of myopia in children is creating a positive outlook for the market. Apart from this, the escalating utilization of orthokeratology, since it aids in reshaping the cornea temporarily, allowing for clearer vision without the need for glasses or contact lenses during the day, is acting as another significant growth-inducing factor. Additionally, the introduction of objective refraction measurement techniques, such as autorefraction and wavefront aberrometry, which provide more accurate as well as consistent measurements than subjective methods, is also augmenting the market growth. Moreover, the emerging popularity of photorefractive keratectomy over LASIK surgery on account of its several associated benefits, including reduced likelihood of corneal ectasia, comparable long-term visual outcomes, lowered risk of flap-related complications like dislocation or infection, etc., is expected to drive the myopia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the myopia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for myopia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myopia market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the myopia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the myopia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current myopia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the myopia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the myopia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the myopia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of myopia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of myopia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of myopia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with myopia across the seven major markets?
• What is the size of the myopia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of myopia?
• What will be the growth rate of patients across the seven major markets?
   

Myopia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for myopia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myopia market?
• What are the key regulatory events related to the myopia market?
• What is the structure of clinical trial landscape by status related to the myopia market?
• What is the structure of clinical trial landscape by phase related to the myopia market?
• What is the structure of clinical trial landscape by route of administration related to the myopia market?